Ryan Allway June 21st, 2022 News, Top News BETHESDA, Md., June 21, 2022–(BUSINESS WIRE)–India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer’s drug development candidate. Researchers at the Jawaharlal Nehru Centre for... Read more
Real Brands Announces Entry to Medical Psychedelics Market, Partners with Marcu & Arora for Licensure, R&D
CBD March 24, 2022
Ryan Allway March 24th, 2022 Psychedelics, Top News Real Brands applying for DEA psychedelics licensure Psychedelics drugs market size is projected to reach $10.75 billion by 2027 Real Brands planning to leverage new clinical research to produce and deliver safe, nature-based psychedelics product formulations that will effectively treat mental... Read more
Ryan Allway March 24th, 2022 News, Top News Cash balance of $18.9 million as of December 31, 2021 Signed out-licensing deal worth $42.7 million with Ewopharma Phase III psoriasis topline data expected Q2 2022 Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Can-Fite’s... Read more
SciSparc Presents New Leadership Lineup
January 27, 2022
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
FSD Pharma Announces Launch of New Corporate Website
January 20, 2022
Ryan Allway January 20th, 2022 News, Psychedelics New Website Shares FSD’s Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders TORONTO, January 20, 2022–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company“), a... Read more
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
January 18, 2022
Ryan Allway January 18th, 2022 The Dual-Site Study Will Be Conducted at the Hannover Medical School in Germany, and Israel’s Tel-Aviv Sourasky Medical Center TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of... Read more
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
September 10, 2021
Ryan Allway September 10th, 2021 Psychedelics The investment provides CaaMTech with capital to advance compounds from its library into clinical trials ISSAQUAH, Wash., Sept. 08, 2021 (GLOBE NEWSWIRE) — CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round,... Read more
Ryan Allway June 25th, 2021 Psychedelics TORONTO, June 25, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce... Read more
Ryan Allway April 7th, 2021 Psychedelics DENVER, April 07, 2021 — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates... Read more
